PHAXIAM Therapeutics S.A. (PHXM) — Cash Flow-to-Debt Ratio
PHAXIAM Therapeutics S.A. (PHXM) has a Cash Flow-to-Debt Ratio of -0.35x as of June 2024, meaning its operating cash flow of €-8.34 Million could theoretically repay 0% of its total liabilities (€23.66 Million) in one year. Explore how much of PHAXIAM Therapeutics S.A.'s assets are long-term investments to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
PHAXIAM Therapeutics S.A. Cash Flow-to-Debt Ratio (2012–2023)
Historical debt coverage capacity for PHAXIAM Therapeutics S.A. across 12 annual periods. Also explore PHAXIAM Therapeutics S.A. asset portfolio for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for PHAXIAM Therapeutics S.A. (2012–2023)
Year-by-year debt coverage analysis for PHAXIAM Therapeutics S.A.. For market capitalisation and broader financial context, see PHAXIAM Therapeutics S.A. stock valuation.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2023 | -0.95x | €-24.43 Million | €25.70 Million | ▲ +33.7% |
| 2022 | -1.43x | €-31.99 Million | €22.32 Million | ▼ -10.1% |
| 2021 | -1.30x | €-57.14 Million | €43.92 Million | ▼ -34.6% |
| 2020 | -0.97x | €-52.05 Million | €53.86 Million | ▲ +26.7% |
| 2019 | -1.32x | €-43.51 Million | €32.99 Million | ▲ +25.3% |
| 2018 | -1.77x | €-39.27 Million | €22.24 Million | ▲ +1.0% |
| 2017 | -1.78x | €-24.70 Million | €13.84 Million | ▲ +5.6% |
| 2016 | -1.89x | €-17.64 Million | €9.33 Million | ▲ +23.8% |
| 2015 | -2.48x | €-14.58 Million | €5.87 Million | ▼ -64.0% |
| 2014 | -1.51x | €-7.24 Million | €4.78 Million | ▼ -2.0% |
| 2013 | -1.48x | €-6.47 Million | €4.36 Million | ▼ -3484.0% |
| 2012 | 0.04x | €621.40K | €14.17 Million | — |